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Zidovudine (ZDV) and clarithromycin (CLR) are often used simultaneously in the management of patients
with AIDS. While pharmacokinetic studies show decreased absorption of ZDV when it is administered with
CLR, it is unknown if CLR affects the intracellular metabolism of ZDV. We investigated the effects of CLR on
the intracellular metabolism of ZDV in vitro. CEM-T4 cells were coincubated with 1 mM ZDV ([3H]ZDV, 3
mCi/ml) either alone or with 1 or 10 mM CLR. Cells were also grown in the presence of CLR for 48 h prior to
exposure to ZDV. Samples were analyzed for mono-, di-, and triphosphate metabolites of [3H]ZDV by
high-performance liquid chromatography separation and radiochemical detection. There were no significant
differences in levels of intracellular metabolites of ZDV following exposure to ZDV, either alone or with 1 or
10 mM CLR and under both coincubated and preincubated conditions. These results show that treatment with
CLR does not alter the formation of phosphorylated metabolites of ZDV in this cell line.
The progression of disease in individuals infected with the
human immunodeficiency virus to AIDS has resulted in the use
of several chemotherapeutic agents to treat the various oppor-
tunistic infections which arise. Zidovudine (ZDV), a first-line
agent used to treat human immunodeficiency virus infection,
and clarithromycin (CLR) are often used simultaneously in the
management of patients infected with human immunodefi-
ciency virus when CD4 cell counts drop below 200 cells per
mm3 because of the emergence of the Mycobacterium
avium-M. intracellulare complex.
ZDV suppression of viral replication is dependent upon
passage of ZDV across cell membranes by both passive diffu-
sion and facilitated processes. Once ZDV is inside the cell,
activation of the drug to the active triphosphate (TP) moiety is
generated by host cellular kinases (4, 14). ZDV is phosphory-
lated to the monophosphate (MP) derivative by thymidine
kinase and then further phosphorylated by thymidylate kinase
to the diphosphate (DP) metabolite. The final step to the TP
form is not clear, but the enzyme involved is presumed to be a
DP kinase. The conversion from the DP form to the active TP
moiety enables the drug to become incorporated into elongat-
ing viral DNA chains and act as a chain terminator of reverse
transcriptase-mediated DNA synthesis. Other factors that in-
fluence ZDV TP production are competition with thymidine,
feedback inhibitors of the pathway, downregulation of en-
zymes, stage of disease, and various drugs which interfere with
thymidine synthesis.
CLR, a macrolide antibiotic, is active against a variety of
organisms including Mycobacterium avium, unlike erythromy-
cin, which has poor activity against mycobacteria. CLR is an
effective inhibitor of RNA-dependent protein synthesis of sus-
ceptible bacteria (8), and a notable feature is its high penetra-
tion into tissue and leukocytes (9).
Initial evidence from pharmacokinetic studies suggests that
CLR interferes with ZDV absorption, leading to slightly de-
creased maximum concentrations in plasma and areas under
the concentration-time curves of ZDV; it has been suggested
that this interaction occurs only when the drugs are adminis-
tered concurrently (5, 10, 11). However, a study with children
found that serum CLR concentrations were unaffected by ei-
ther ZDV or didanosine (6). Since these previous studies ad-
dressed only drug pharmacokinetics in serum, it is unknown
whether CLR might also affect the intracellular metabolism of
ZDV. Mechanisms that could be affected by the macrolide
could include the alteration of the synthesis of key enzymes
known to activate ZDV and the passage of ZDV into cells.
This study investigated the effects of CLR on the intracellular
metabolism of ZDV in vitro.
(This work was presented in part at the 34th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Or-
lando, Fla., October 1994 [11a]).
ZDV (Burroughs Wellcome Co., Research Triangle Park,
N.C.) and CLR (Abbott Laboratories, Abbott Park, Ill.) were
dissolved in media, sterile filtered, and diluted to the appro-
priate concentrations in modified RPMI 1640 media contain-
ing L-glutamine, fetal bovine serum, and 25 mM HEPES (N-
2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid) buffer
(Life Technologies, Grand Island, N.Y.).
Continuous cultures of CEM-T4 lymphocytes (National In-
stitutes of Health AIDS Research and Reagent Program, Og-
den Bioservices Corp., Rockville, Md.) grown in media sup-
plemented with 10% fetal bovine serum were used in all
studies. The doubling time of cells grown in a humidified in-
cubator at 378C in a 5% CO2 atmosphere was approximately
24 h. CEM-T4 cell growth and cell viability over 5 days were
not affected by the two drugs, either alone or in combination;
thus, no cytotoxicity was observed. Cell counts and viability
were determined daily with trypan blue exclusion. All experi-
ments were performed in duplicate.
Five to ten million CEM-T4 cells were coincubated for 24 h
with 1 mM ZDV ([3H]ZDV, 3 mCi/ml [Moravek Biochemicals,
Brea, Calif.]) alone or with 1 or 10 mM CLR in a final volume
of 10 ml of modified RPMI 1640 medium. Cells were also
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grown in the presence of CLR for 48 h; this was followed by
addition of ZDV and incubation for an additional 24 h. After
the 24-h incubation with ZDV, cells were centrifuged and the
medium was removed. The cells were then washed twice with
10 ml of phosphate-buffered saline (PBS). Phosphorylated me-
tabolites were extracted with 200 ml of 0.2 N perchloric acid for
30 s. After centrifuging, supernatants were transferred to clean
tubes, neutralized with equivalent amounts of sodium hydrox-
ide, and frozen until the assay. All experiments were per-
formed in triplicate.
Samples were analyzed for [3H]ZDV MP, DP, and TP me-
tabolites by high-performance liquid chromatography separa-
tion and radiochemical detection (12). The phosphorylated
metabolites were separated with an anion-exchange column
(Whatman SAX-10, 4.6 mm by 25.0 cm) and eluted from the
column at 1 ml/min by using a 45-min linear gradient of 10 mM
NaH2PO4 (pH 3.5) to 500 mM NaH2PO4–500 mM KCl (pH
3.5). The column eluent was monitored by UV detection at 254
nm and by a Radiomatic scintillation detector (Rainin Instru-
ment Co., Medford, Mass.) connected in-line. The column
retention times for ZDVMP, ZDV DP, and ZDV TP were 10,
25, and 50 min, respectively. The quantity of each ZDV me-
tabolite was represented as picomoles per 106 cells, and the
calculation was based on the integrated peak area of the ra-
diochromatogram for each metabolite, the specific activity of
the radiolabelled drug, and the number of cells analyzed.
[3H]TTP was used as a marker for recovery of ZDV TP and
was added (1 mCi) to drug-free samples after removal of the
final wash with PBS. An aliquot of supernatant was quantitated
for radioactivity by liquid scintillation, as was the pellet. Less
than 5% of total radioactivity was lost to the pellet. The inter-
day amount recovered in the supernatant was 73%, with an
interday precision of 7.6%.
Differences in the phosphorylated metabolites in the differ-
ent groups were assessed with one-way analysis of variance in
which an a value of 0.05 was used to define significance.
The most abundant intracellular ZDV metabolite in
CEM-T4 cells after 24 h was MP under all conditions; DP and
TP were formed in much smaller quantities. When cells were
incubated with 1 mM CLR, the amounts of phosphorylated
ZDV metabolites generated were similar to the amounts gen-
erated by cells not incubated with CLR (Fig. 1). The amounts
of intracellular metabolites were also not different when cells
were coincubated or preincubated with 10 mM CLR. The pro-
portion represented by TP, the most important derivative, was
similar under all conditions, as were the ratios of MP to TP
(Table 1). The variation in MP/TP ratios can be explained by
the variation in the MP metabolite.
The concentrations of drugs tested in this study were similar
to those achieved clinically. Following an oral 200-mg dose of
ZDV in humans, maximum concentrations in plasma of 3 to 4
mM are achieved (13). Concentrations of ZDV in plasma fall
rapidly to less than 1 mM over the dosing interval of 8 h.
Maximum concentrations in plasma of 2.7 mM (2.1 mg/ml)
were achieved for CLR after an oral 500-mg dose (3). There-
fore, experimental conditions of 1 and 10 mM CLR repre-
sented concentrations observed after single and multiple oral
doses in humans.
All newer macrolides are known to accumulate in tissue,
thereby achieving higher concentrations than those in serum.
The intracellular concentration of CLR has been shown to be
9-fold to 16-fold higher than the extracellular concentration in
human neutrophils and polymorphonuclear leukocytes (1, 7).
The results from this study show no changes in the ability of
this cell line to phosphorylate ZDV when CLR was present.
The presence of DP and TP in much smaller quantities is
reflective of a rate-limiting conversion from MP to DP, which
is consistent with quantities reported in other studies (2, 4).
The significance of these results appears to be that no rou-
tine drug adjustment is warranted in the clinical setting. Po-
tential interactions could still occur between other antiretrovi-
ral agents and CLR. In addition, other macrolides may affect
the intracellular metabolism of ZDV and the other antiretro-
viral agents. Further studies may be needed to investigate these
potential interactions.
This work was supported in part by Abbott Laboratories.
REFERENCES
1. Anderson, R., G. Joone, and C. E. J. Van Rensburg. 1988. An in-vitro
evaluation of the cellular uptake and intraphagocytic bioactivity of clarithro-
mycin (A-56268, TE-031), a new macrolide antimicrobial agent. J. Antimi-
crob. Chemother. 22:923–933.
2. Avramis, V. I., W. Markson, R. L. Jackson, and E. Gomperts. 1989. Bio-
chemical pharmacology of zidovudine in human T-lymphoblastoid cells
(CEM). AIDS 3:417–422.
3. Chu, S., D. S. Wilson, R. L. Deaton, A. V. Mackenthun, C. N. Eason, and
J. H. Cavanaugh. 1993. Single- and multiple-dose pharmacokinetics of cla-
rithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719–726.
4. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A.
Freeman, S. Nusinoff-Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and
D. W. Barry. 1986. Phosphorylation of 39-azido-39-deoxythymidine and se-
lective interaction of the 59-triphosphate with human immunodeficiency vi-
rus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333–8337.
5. Gustavson, L. E., S. Chu, A. Mackenthun, S. D. Gupta, and J. C. Craft. 1991.
FIG. 1. Intracellular phosphorylated metabolites of ZDV after incubation
with 1 mM ZDV alone (hatched bars), after incubation with ZDV and 1 mM
CLR (white bars), and after 48 h of preincubation with 1 mM CLR (black bars).
Data are means 6 standard errors of the means (n 5 3).




[3H]ZDV as TP MP/TP ratio
ZDV alone 2.2 6 0.2 47.1 6 3.8
ZDV with 1 mM CLR
Coincubated 2.1 6 0.04 47.2 6 0.9
Preincubated 48 h 2.06 0.2 51.2 6 6.8
ZDV with 10 mM CLR
Coincubated 2.9 6 0.7 37.1 6 6.9
Preincubated 48 h 2.06 0.2 51.1 6 5.1
a Values are means 6 standard errors of the means. Differences were not
statistically significant.
1946 NOTES ANTIMICROB. AGENTS CHEMOTHER.
 o
n







Drug interaction between clarithromycin and oral zidovudine in HIV-1 in-
fected patients. Clin. Pharmacol. Ther. 53:163.
6. Husson, R. N., L. A. Ross, S. Sandelli, C. B. Inderlied, D. Venzon, L. L.
Lewis, L. Woods, P. S. Conville, F. G. Witebsky, and P. A. Pizzo. 1994. Orally
administered clarithromycin for the treatment of systemic Mycobacterium
avium complex infection in children with acquired immunodeficiency syn-
drome. J. Pediatr. 124:807–814.
7. Ishiguro, M., H. Koga, S. Kohno, T. Hayashi, K. Yamaguchi, and M. Hirota.
1989. Penetration of macrolides into human polymorphonuclear leucocytes.
J. Antimicrob. Chemother. 24:719–729.
8. Neu, H. C. 1991. The development of macrolides: clarithromycin in perspec-
tive. J. Antimicrob. Chemother. 27(Suppl. A):1–9.
9. Peters, D. H., and S. P. Clissold. 1992. Clarithromycin. A review of its
antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Drugs 44:117–164.
10. Petty, B., M. Polis, S. Haneiwich, M. Dellerson, J. C. Craft, and R. Chaisson.
1992. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV
patients, abstr. 24, p. 114. In Program and abstracts of the 32nd Interscience
Conference on Antimicrobial Agents and Chemotherapy. American Society
for Microbiology, Washington, D.C.
11. Polis, M. A., S. Haneiwich, J. A. Kovacs, R. T. Davey, R. E. Walker, J.
Falloon, G. Galetto, J. Metcalf, M. Amantea, M. Dellerson, S. Schlager, C.
Craft, B. Petty, H. C. Lane, and H. Masur. 1991. Dose escalation study to
determine the safety, maximally tolerated dose (MTD), and pharmacokinet-
ics of clarithromycin (clari) with zidovudine (zdv) in HIV-infected persons,
abstr. 238, p. 138. In Program and abstracts of the 31st Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy. American Society for
Microbiology, Washington, D.C.
11a.Rana, K. Z., J. W. Darnowski, D. A. Copeland, A. H. Strayer, P. E. Pivarnik,
and M. N. Dudley. 1994. Clarithromycin (CLR) does not affect intracellular
concentrations of phosphorylated metabolites of zidovudine (ZDV), abstr.
I197, p. 211. In Abstracts of the 34th Interscience Conference on Antimi-
crobial Agents and Chemotherapy. American Society for Microbiology,
Washington, D.C.
12. Tosi, P., P. Calabresi, F. A. Goulette, C. A. Renaud, and J. W. Darnowski.
1992. Azidothymidine-induced cytotoxicity and incorporation into DNA in
the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro
and in vivo. Cancer Res. 52:4069–4073.
13. Unadkat, J. D., A. C. Collier, S. S. Crosby, D. Cummings, K. E. Opheim, and
L. Corey. 1990. Pharmacokinetics of oral zidovudine (azidothymidine) in
patients with AIDS when administered with and without a high-fat meal.
AIDS 4:229–232.
14. Yarchoan, R., H. Mitsuya, C. E. Myers, and S. Broder. 1989. Clinical phar-
macology of 39-azido-29,39-dideoxythymidine (zidovudine) and related
dideoxynucleosides. N. Engl. J. Med. 321:726–737.
VOL. 40, 1996 NOTES 1947
 o
n
 August 23, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
